This is a preview of subscription content, log in to check access.
Buy single article
Instant access to the full article PDF.
Price includes VAT for USA
Inpharma Weekly provides rapid alerts to news on drugs and drug therapy. Summarizing information selected from over 1600 biomedical journals, this newsletter is produced by Adis International Limited and is available in a variety of formats. Please contact your nearest Adis office for subscription details.
Normalized diastolic BP was defined as a BP of <90mm Hg.
The maximum infusion rate for abciximab was 10 μg/min.
Abciximab and tirofiban were initially administered as IV boluses of 0.25 mg/kg and 10 μg/kg, respectively. All patients received aspirin 250 to 500mg within 24 hours of surgery and 75 to 325 mg/day thereafter.
Costs (1999 values) included those related to additional events and procedures, hospitalization and physicians’ services.
Normal blood cholesterol levels were defined as LDL-cholesterol levels of <3 mmol/L or total cholesterol of <5 mmol/L at baseline.
Costs included those for drug acquisition, hospitalization, physician services, laboratory services and complications.
The trials included the Evaluation of Xemilofiban in Controlling Thrombotic Events (EXCITE), Orbofiban in Patients with Unstable Angina (OPUS), Sibrafiban versus aspirin to Yield Maximum Protection from ischemic Heart events post-acute cOroNary sYndromes (SYMPHONY), and 2nd SYMPHONY.
Husted SE, Wallentin L, Lagerqvist B, et al. Benefits of extended treatment with dalteparin in patients with unstable coronary artery disease eligible for revascularization. Eur Heart J 2002; 23 (15): 1213–8
Verheugt FWA. Low molecular weight heparin: a bridge over troubled water. Eur Heart J 2002; 23 (15): 1144–6
Hongo RH, Ley J, Dick SE, et al. The effect of Clopidogrel in combination with aspirin when given before coronary artery bypass grafting. J Am Coll Cardiol 2002; 40: 231–7
Nelson HD, Humphrey LL, Nygren P, et al. Postmenopausal hormone replacement therapy: scientific review. JAMA 2002; 288: 872–81
O’Grady NP, Alexander M, Patchen Dellinger E, et al. Guidelines for the prevention of intravascular catheter-related infections. MMWR Morbid Mortal Wkly Rep 2002; 51: 1–32
Glassman AH, O’Connor CM, Califf RM, et al. Sertraline treatment of major depression in patients with acute MI or unstable angina. JAMA 2002; 288: 701–9
Carney RM, Jaffe AS. Treatment of depression following acute myocardial infarction. JAMA 2002; 288: 750–1
Wagner A, Herkner H, Schreiber W, et al. Ramipril prior to thrombolysis attenuates the early increase of PAI-1 in patients with acute myocardial infarction. Thromb Haemost 2002; 88: 180–5
Kjeldsen SE, Hedner T, Syvertsen JO, et al. Influence of age, sex and blood pressure on the principal endpoints of the Nordic Diltiazem (NORDIL) Study. J Hyperten 2002; 20: 1231–7
Thijs L, Staessen JA, Wang J, et al. Subgroup analysis of the NORDIL trial. J Hyperten 2002; 20: 1085–7
Lemaitre RN, Psaty BM, Heckbert SR, et al. Therapy with hydroxymethylglutaryl coenzyme A reductase inhibitors (statins) and associated risk of incident cardiovascular events in older adults: evidence from the Cardiovascular Health Study. Arch Intern Med 2002; 162: 1395–400
Grundy SM. Statin therapy in older persons: pertinent issues. Arch Intern Med 2002; 162: 1329–31
Blake GJ, Ridker PM, Kuntz KM. Projected life-expectancy gains with statin therapy for individuals with elevated C-reactive protein levels. J Am Coll Cardiol 2002; 40: 49–55
Nakov R, Pfarr E, Eberle S, et al. Darusentan: an effective endothelin(A) receptor antagonist for treatment of hypertension. Am J Hyperten 2002; 15: (Pt 1) 583–9
Olschewski H, Simonneau G, Galié; N, et al. Inhaled iloprost for severe pulmonary hypertension. N Engl J Med 2002; 347: 322–9
Madrid AH, Bueno MG, Rebollo JMG, et al. Use of irbesartan to maintain sinus rhythm in patients with long-lasting persistent atrial fibrillation: a prospective and randomized study. Circulation 2002; 106: 331–6
Moliterno DJ, Yakubov SJ, DiBattiste PM, et al. Outcomes at 6 months for the direct comparison of tirofiban and abciximab during percutaneous coronary revascularisation with stent placement: the TARGET follow-up study. Lancet 2002; 360: 355–60
Roffi M, Moliterno DJ, Meier B, et al. Impact of different platelet glycoprotein IIb/IIIa receptor inhibitors among diabetic patients undergoing percutaneous coronary intervention: Do Tirofiban and ReoPro give Similar Efficacy Outcomes Trial (TARGET) 1 -year follow-up. Circulation 2002; 105: 2730–6
Stone GW, Moliterno DJ, Bertrand M, et al. Impact of clinical syndrome acuity on the differential response to 2 glycoprotein IIb/IIIa inhibitors in patients undergoing coronary stenting: the TARGET trial. Circulation 2002; 105: 2347–54
Follath F, Cleland JGF, Just H, et al. Efficacy and safety of intravenous levosimendan compared with dobutamine in severe low-output heart failure (the LIDO study): a randomised double-blind trial. Lancet 2002; 360: 196–202
Ko DT, Hebert PR, Coffey CS, et al. Beta-blocker therapy and symptoms of depression, fatigue, and sexual dysfunction. JAMA 2002; 288: 351–7
Casciano R, Doyle JJ, Chen J, et al. Economic benefits of amlodipine treatment in patients with coronary artery disease. Pharmacoeconomics 2002; 20 (8): 553–63
Billheimer JT, Dicker IB, Wynn R, et al. Evidence that thrombocytopenia observed in humans treated with orally bioavailable glycoprotein IIb/IIIa antagonists is immune mediated. Blood 2002; 99: 3540–6
Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20 536 high-risk individuals: a randomised placebo-controlled trial. Lancet 2002; 360: 7–22
Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of antioxidant vitamin supplementation in 20 536 high-risk individuals: a randomised placebo-controlled trial. Lancet 2002; 360: 23–33
Yusuf S. Two decades of progress in preventing vascular disease. Lancet 2002; 360: 2–3
Compton A. A practical cost analysis of bivalirudin. Pharmacotherapy 2002; 22: 119S–27S
Newby LK, Califf RM, White HD, et al. The failure of orally administered glycoprotein IIb/IIIa inhibitors to prevent recurrent cardiac events. Am J Med 2002; 112: 647–58
Cannon CP. Oral glycoprotein IIb/IIIa inhibition — great idea, but it didn’t work. Am J Med 112: 673-5
About this article
Cite this article
Opinion and Evidence in Cardiovascular Therapeutics. Am J Cordiovosc Drugs 2, 345–353 (2002). https://doi.org/10.2165/00129784-200202050-00009